NightBalance acquired by Royal Philips - Gilde Healthcare

NightBalance acquired by Royal Philips

May 8, 2018

Utrecht, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has acquired NightBalance, a portfolio company from specialist investor Gilde Healthcare. Netherlands-based NightBalance is a digital health scale-up company commercializing an innovative, easy to use device to treat positional obstructive sleep apnea and positional snoring. With the acquisition of NightBalance, Philips expands its Sleep & Respiratory Care portfolio. Financial details of the transaction were not disclosed.

NightBalance’s Sleep Position Trainer (SPT) was designed as a patient friendly treatment alternative for people who suffer from positional obstructive sleep apnea. The SPT gently prompts them not to sleep on their back, avoiding the apneas from occurring during sleep. The SPT is CE-marked and is currently marketed in select countries in Europe. The acquisition will help Philips to further expand its leadership position in the growing home care market, and its ability to deliver integrated solutions that drive efficiencies and improved outcomes. Philips already offers a broad range of care solutions for people living with obstructive sleep apnea.

 

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in digital health, medtech and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market.
For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...
March 21, 2024

Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I

Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has reached a binding agreement to sell its majority stake in RAD-x to a consortium of Swiss Life Asset Managers and Vesper Next Generation...
March 18, 2024

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
February 29, 2024